Moleculin Biotech, Inc.

Equities

MBRX

US60855D3098

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
4.63 ^USD	+7.47%		-0.43%	-64.04%

Apr. 18	Sector Update: Health Care Stocks Ease in Afternoon Trading	MT
Apr. 18	Moleculin Biotech Secures Orphan Drug Label For Annamycin in EU	MT

Moleculin Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 22, 2024 at 04:06 pm EDT

Moleculin Biotech, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 29.77 million compared to USD 29.03 million a year ago. Basic loss per share from continuing operations was USD 15.07 compared to USD 15.22 a year ago.

Latest news about Moleculin Biotech, Inc.

Sector Update: Health Care Stocks Ease in Afternoon Trading	Apr. 18	MT
Moleculin Biotech Secures Orphan Drug Label For Annamycin in EU	Apr. 18	MT
Top Premarket Decliners	Apr. 16	MT
Transcript : Moleculin Biotech, Inc. - Special Call	Mar. 28
Sector Update: Health Care Stocks Advance Late Afternoon	Mar. 27	MT
Sector Update: Health Care	Mar. 27	MT
Moleculin Biotech Shares Rise Following Patent Announcement	Mar. 27	MT
Maxim Adjusts Price Target on Moleculin Biotech to $20 From $45, Maintains Buy Rating	Mar. 26	MT
Transcript : Moleculin Biotech, Inc., 2023 Earnings Call, Mar 25, 2024	Mar. 25
Moleculin Biotech, Inc Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial	Mar. 25	CI
Moleculin Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 22	CI
North American Morning Briefing : Markets on Hold as Fed Decision Nears	Mar. 20	DJ
Moleculin Biotech to Effect 1-For-15 Reverse Stock Split to Regain Compliance	Mar. 19	MT
Transcript : Moleculin Biotech, Inc. - Special Call	Feb. 28
Transcript : Moleculin Biotech, Inc. - Special Call	Feb. 14
Moleculin Biotech, Inc. Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3	Jan. 24	CI
Moleculin Biotech, Inc. announced that it expects to receive $9.01739 million in funding	Dec. 19	CI
Transcript : Moleculin Biotech, Inc. - Special Call	Dec. 17
HC Wainwright Initiates Moleculin Biotech With Buy Rating, Price Target is $3	Dec. 14	MT
Moleculin Biotech Reports Positive Interim Data in Annamycin Trials; Shares Rise	Nov. 13	MT
Transcript : Moleculin Biotech, Inc., Q3 2023 Earnings Call, Nov 13, 2023	Nov. 13
Moleculin Biotech, Inc. Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months	Nov. 13	CI
Moleculin Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Moleculin Reports Positive Preliminary Findings From Phase 1B/2 Lung Metastases Trial; Shares Rise	Nov. 06	MT
Moleculin Biotech, Inc. Announces Completion of Enrollment in U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases	23-09-21	CI

Chart Moleculin Biotech, Inc.

Duration

Period

More charts

Company Profile

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company. The Company has a pipeline of clinical programs for the treatment of tumors and viruses. It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

4.63 USD

Average target price

35 USD

Spread / Average Target

+655.94%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MOLECULIN BIOTECH, INC.	-64.04%	10.31M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs